Abstract. Radiation with or without chemotherapy is considered the mainstay of treatment for the majority of patients with oropharyngeal cancer. The goal of this study was to analyze competing causes of mortality in patients with oropharyngeal cancer with long-term follow-up. We queried the Surveillance, Epidemiology and End Results (SEER) database and identified 3728 patients with oropharyngeal cancer treated between 1988 and 2001 with definitive radiotherapy. We analyzed predictors of overall survival and risks of mortality from index oropharyngeal cancer, second primary cancer, cardiovascular disease and other causes using a cumulative incidence analysis and Cox multivariate analysis. With a median follow-up of 6.8 years, the 5-and 10-year overall survival was 37 and 22%, respectively. At 5 years, the risk of mortality from primary oropharyngeal cancer was 35%. Between years 3 and 10, 69% of mortalities were attributed to causes other than the index cancer. Despite advances in the non-surgical treatment of oropharyngeal cancer, patients remain at significant risk of cancer-and non-cancer-related mortality.
Introduction
The majority of patients treated with definitive radiotherapy with or without chemotherapy in recent locally advanced head and neck cancer trials are oropharyngeal cancer patients (1) (2) (3) . The incidence of base of tongue and tonsil cancer in younger patients has increased dramatically over the past three decades (4) . Several strategies designed to improve locoregional control for locally advanced oropharyngeal cancers, including concurrent chemoradiotherapy, intensity modulated radiation therapy and altered fractionation radiation therapy, have been extensively investigated (5) (6) (7) (8) (9) . However, curing the index cancer eliminates only one of several mortality risks faced by these patients (10) . Due to competing risks of second primary cancer and comorbid medical conditions related to smoking and alcohol use, overall survival remains consistently lower than disease-free survival (11) . Recently, high-risk human papilloma virus (HPV) infection has emerged as an important risk factor for oropharyngeal carcinoma (12) . HPV infection is now found in more than 50% of patients with oropharyngeal cancer and tends to affect younger patients irrespective of tobacco or alcohol use (13) . Preliminary data suggest that these patients are at lower risk for second primary cancers due to the focal nature of HPV infection (14) . Furthermore, since these patients tend to be younger and are less likely to be heavy users of tobacco, they may also be at lower risk for cardiovascular disease (13, 15) . To evaluate the different causes of mortality in patients with oropharyngeal carcinoma treated with radiotherapy, we conducted an analysis of the SEER database.
Materials and methods
Patient selection. The patient population in this study consisted of adult patients with stage I-IVb oropharyngeal squamous cell carcinoma diagnosed between 1988 and 2001 in the Surveillance, Epidemiology, and End Results (SEER) 17 database, who had been treated with definitive radiotherapy. The SEER17 database is a longitudinal database that collects information from 17 cancer registries covering 26% of the US population. The SEER17 database is composed of 17 population-based cancer registries from Connecticut, New Jersey, Atlanta, Kentucky, Louisiana, rural Georgia, Detroit, Iowa, Hawaii, New Mexico, Seattle-Puget Sound, Utah, San Francisco-Oakland, San Jose-Monterey, Los Angeles, greater California and the Alaska Native Tumor Registry. Serial registry data are de-identified and submitted to the U.S. National Cancer Institute on a bi-annual basis and these data are publicly available for investigators (16) . Therefore, approval by an ethics committee was not necessary to perform the analyses. The population covered by the SEER database is considered representative of the US population and the case ascertainment rate is reportedly 97.5% (16 Overall survival was calculated from the time of diagnosis to the time of mortality or last follow-up using the Kaplan-Meier method. Causespecific mortality was calculated from the time of diagnosis to the time of event or last follow-up. We analyzed the actuarial rates of cause-specific mortality using the cumulative incidence method described by Coviello et al using Stata 9.1 (17) . When there are competing risks, the Kaplan-Meier method for estimation of cumulative incidence curves is considered inaccurate (18) . For overall survival, the stratified log-rank test was utilized to compute survival estimates that were within specified strata levels. Results were considered to indicate a statistically significant difference at P-values <0.05.
Cox proportional hazards regression modeling was limited to covariates that were found to be statistically significant on univariate analysis. A multivariate Cox analysis was developed to calculate the adjusted hazards ratios (HRs) and 95% confidence intervals (95% CIs) for 1737 patients with complete datasets. Separate multivariate models were developed for specific causes of cancer mortality. A formal examination of the proportional hazards assumption was performed graphically by plotting -log(log(S(t)) versus log(t) for each covariate. This confirmed that the covariates are independent with respect to time and their HRs are constant over the clinically relevant period of follow-up.
Results
Outcomes. The 5-and 10-year overall survival was 37 and 22%, respectively (Fig. 1A) . Median follow-up for surviving patients was 6.8 years (range, 0.1-18.8). Predictors of decreased survival on univariate analysis included advanced age, African descent, earlier date of diagnosis, non-married, prior cancer, well or moderately differentiated disease, subsite other than tonsil or base of tongue, advanced T stage and advanced nodal disease (Table I) . Gender was not significant on univariate analysis. There was no significant difference by nodal status of N0 to N2a (p=0.14) or between tonsil vs. base of tongue (p=0.28).
Causes of mortality.
To date, the causes of mortality included none (n=942, 25%), primary oropharyngeal cancer (n=1428, 38%), second primary cancer (n=613, 16%), cardiovascular (n=318, 9%) and other causes (n=427, 11%). Various types of mortality occurred in different patterns. The 5-and 10-year risk of mortality from primary cancer was 35 and 37% (Fig. 1B) . The 5 and 10-year risk of mortality from second primary cancers was 16 and 21%, respectively (Fig. 1C) . The 5-and 10-year risk of cardiovascular mortality was 5 and 9% (Fig. 1D) . The 5-and 10-year risk of mortality from other causes was 7 and 11% (Fig. 1E) . While 60% of mortalities within the first 3 years of diagnosis of cancer were classified as oral cavity or oropharyngeal cancers, 69% of mortalities after 3 years were related to second primaries, cardiovascular disease or second primary cancers.
Multivariable analyses.
On Cox regression analysis, all available prognostic factors were predictive of overall survival (Table II) . The strongest predictors of decreased survival in order of significance, were advanced age, African descent, single marital status, advanced T stage, advanced N stage and well/moderately differentiated disease. Separate multivariable analyses of causes of mortality demonstrate that different prognostic factors are implicated (Table III) . Age, advanced nodal disease, advanced T stage, well/moderately differentiated disease, African descent and unmarried status were associated with greater risk of mortality from primary oropharyngeal cancer. Predictors of mortality from second cancer were non-HPV-associated subsite, prior cancer diagnosis, advanced age, male gender and well/moderately differentiated disease. Risk factors associated with mortality from cardiovascular disease were advanced age, African ethnicity, male gender and prior diagnosis of cancer. Only advanced age and unmarried status predicted for mortality from other causes.
Discussion
Treatment of primary oropharyngeal cancer. Despite advances in non-surgical therapy for oropharyngeal cancer over the past two decades, patients remain at significant risk of mortality from primary cancer (1, (5) (6) 8) . Since the majority of deaths occurring in the first 5 years following diagnosis are attributed to primary cancer, further improvements in therapy would yield meaningful improvements in overall survival (19) . The improved prognosis associated with oropharyngeal cancers in recent years may be related to increased utilization of concurrent chemoradiation, technological advances in radiation delivery and the increasing prevalence of HPV-related tumors (5, 9, 12) . Caucasian ethnicity and high grade tumors have both been associated with HPV-related tumors and likely account for some of the improved prognosis observed in those subgroups (13, 20) . The 5-year overall survival among patients of African descent was only 24%. Consistent with previously published work, efforts to improve outcome in African-American patients by earlier diagnosis and improved treatment for HPV-negative disease are urgently required (20) .
Treatment of elderly patients remains a challenge due to the increased difficulty of administering therapy to this cohort (21). The 5-year overall survival for the >70 year old population is 26%. Two recent meta-analyses suggest that neither concurrent chemotherapy nor altered fractionation radiation therapy were beneficial for patients older than 70 years of age, at least partly due to the high risk of mortality from comorbid illness (5, 22) . Whether better-tolerated combined modality treatments, such as concurrent cetuximab and radiotherapy, will improve outcome is currently unknown (1, 23) . As expected, advanced T and N stage (≥N2B) predicted an increased risk of mortality from primary oropharyngeal cancer (24) . Based on the historically poor survival of patients with T3-4 or N2c-N3 disease, good performance status patients with high-risk disease are an appropriate population of patients to investigate intensification of therapy beyond concurrent chemoradiotherapy by adding induction chemotherapy, altered fractionation radiation and/ or biologically targeted therapy (3,25-26) . The association of 
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unmarried status with mortality from primary oropharyngeal cancer is largely unexplained (16) . Unmarried patients may lack social support and are at higher risk for pretreatment health behaviors such as tobacco and alcohol abuse, poor diet and limited physical activity (27) .
Mortality from second primary cancer, cardiovascular disease and other causes. Between years 5 and 10 following diagnosis, 41% of 5-year survivors succumbed to the disease. During this interval, 73% of mortalities were attributed to diagnoses other than oral cavity or oropharyngeal cancer.
As the long-term survival of head and neck cancer continues to improve, identifying strategies to prevent late events may become increasingly important. In contrast to field cancerization associated with tobaccoand alcohol-related upper aerodigestive tumors, oral HPV infection is generally focal (13) . Emerging data suggest that HPV-related patients have a lower risk of second malignancies (14) . Consistent with this theory, patients more likely to harbor HPV-positive tumors, such as those of younger age, female gender, tonsil or base of tongue subsite and high-grade disease, have a lower risk of mortality from second cancer (13) . Given the increased risk of cancer associated with tobacco use, prior diagnosis of cancer may be a surrogate for smoking status (28) . In this study, we also identified a cohort of patients at increased risk of cardiovascular disease and mortality from other causes. Several risk factors overlap with those associated with second cancers (male gender and prior cancer diagnosis), indicating that tobacco use is the common risk factor. African-American patients and the elderly appear to be at particularly high risk for mortality from cardiovascular disease. Increased surveillance and optimal medical management appear appropriate for these subgroups (29) .
Limitations. It is important to acknowledge the limitations of this retrospective analysis of the SEER registry. Several important factors, including HPV status, performance status, concurrent administration of chemotherapy and details of radiation delivery, are not available for analysis. Accurate attribution of cause of mortality is always a potential source of error. Within the limitations of diagnosis codes, it is not always possible to accurately classify mortality from primary or secondary cancer. For this analysis, we classified mortality from oral cavity or oropharyngeal cancer as primary disease. This is necessary since in the SEER site recode schema, base of tongue cancer is subclassified under oral cavity rather than oropharyngeal cancer. Despite these limitations, these data provide useful insight into the competing risks of mortality of patients with oropharyngeal cancer and may help to assist with future clinical trial design for this patient population.
In conclusion, although the prognosis of patients with oropharyngeal cancer treated with radiotherapy has improved in recent years, the 5-year overall survival remains below 50%. Earlier diagnosis and more effective cancer therapy is required to further improve the 5-year survival, while reducing mortality from other causes may impact the 10-year survival.
